कंपनी का अवलोकन
TG Therapeutics, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases across the United States and international markets. The company functions within the Healthcare sector, specifically inside the Biotechnology industry, which implies a focus on high-risk, high-reward research and development cycles aimed at creating differentiated therapeutic assets. Its current market capitalization stands at $5.46B, while the firm reports trailing twelve-month revenue of $616.29M and employs a workforce of 399 individuals. These valuation and revenue figures indicate that TGTX possesses a significant market presence relative to early-stage biotech firms, suggesting a level of operational maturity and product pipeline commercialization that allows for substantial annual income generation without reliance on venture capital funding.
वित्तीय स्वास्थ्य
The company recorded a trailing twelve-month revenue of $616.29M and generated a net income of $447.18M, supported by an EBITDA of $123.38M. The substantial gap between the revenue figure and the net income figure reveals a highly efficient cost structure where operating expenses are significantly lower than total sales, resulting in a profit margin of 72.6%. However, the free cash flow stands at -$43,978,876, indicating that despite accounting profitability, the company is currently investing heavily in operations or growth initiatives that exceed its cash generation in the short term. The gross margin is reported at 83.7%, demonstrating the high value-added nature of the pharmaceutical products, while the operating margin sits at 26.2%, reflecting the scale of administrative and research costs required to maintain the business. In terms of liquidity, total cash holdings of $141.97M are outweighed by total debt of $254.40M, which necessitates careful management of refinancing or cash flow generation. The debt-to-equity ratio is 39.26, suggesting a leveraged balance sheet where equity capital is significantly lower than debt obligations. Nevertheless, the current ratio of 4.10 indicates a robust short-term liquidity position, as current assets are more than four times current liabilities, providing ample buffer for immediate obligations. Furthermore, the return on equity is an impressive 102.8% and the return on assets is 9.4%, metrics that reveal management's effectiveness in generating substantial returns on shareholder capital relative to the asset base employed.
मूल्यांकन आकलन
The trailing P/E ratio is 12.35, while the forward P/E is projected at 13.89, implying that the market expects earnings growth to moderate slightly or that current earnings are elevated relative to future projections. The price-to-book ratio stands at 7.57, which indicates a significant market premium over the company's book value, a common characteristic for biotechnology firms with valuable intangible assets like intellectual property. Alternative valuation metrics such as the price-to-sales ratio of 8.86 and an EV/EBITDA of 41.86 suggest that investors are pricing in substantial future growth potential from the product pipeline. The stock has traded between a 52-week low of $25.28 and a 52-week high of $46.48, meaning the current price sits within this historical range but remains volatile. The beta value is 1.75, which signifies that the stock price volatility is substantially higher than that of the broader market, moving with greater intensity during periods of market turbulence.
Growth & Income
Revenue growth year-over-year is 78.0%, whereas earnings growth year-over-year is -6.1%, indicating that earnings are growing slower than revenue, which implies that the expansion in sales has not yet fully translated into proportional profit increases, possibly due to increased costs or one-time expenses. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning it reinvests all earnings back into research, development, and commercialization rather than distributing them to shareholders. This strategy prioritizes long-term asset growth and pipeline expansion over immediate income distribution for investors. The overall growth and income profile is characterized by aggressive top-line expansion in a specialized therapeutic area, coupled with a deliberate absence of dividend payments to fuel operational scaling.